An Open-label, 2 x 2 Factorial, Randomized controlled, clinical trial to evaluate the safety of apixaban vs Vitamin K antagonist and Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention
Ficha Técnica
Investigador Principal
DJORDJE PAVLOVIC DJUROVIC
Promotor
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)